Oncology Biotech CEO Activates “Latent Viral Side” Against COVID-19

In every National Football League game, athletes must accomplish two difficult things that rest at opposite ends of the spectrum: rigor and speed. If their movements are off by even half a second, they risk being tackled by their opponent. Game over. In this COVID-19 day and age, believe it or not, the NFL serves … Continue reading “Oncology Biotech CEO Activates “Latent Viral Side” Against COVID-19″

Dramatic Changes in Hepatitis C Treatment Expected to Continue

Earlier this year the FDA approved telaprevir (Incivek) from Vertex Pharmaceuticals and boceprevir (Victrelis) from Merck for the treatment of hepatitis C. Both agents are protease inhibitors and represent the first approvals of direct acting antivirals for hepatitis C. Direct acting antivirals are a broad class of agents that act to block the growth of … Continue reading “Dramatic Changes in Hepatitis C Treatment Expected to Continue”

Combination Drugs Are The Future for Hepatitis C

Combination therapy has been a central component of treatment for certain viral diseases for more than 15 years. The benefits of combination therapy can arise from activation of multiple host pathways, suppression of mutational variants that can lead to viral escape, or perhaps both. In HIV, the benefit of combination therapy is due to suppression … Continue reading “Combination Drugs Are The Future for Hepatitis C”